Superworth

Cardiff Oncology CRDF

Biotechnology, Healthcare
$0.84
−5.09%
Market cap
$65.7M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
129×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$508K
−7% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
n/m
not a meaningful number

Cardiff Oncology trades at 129× sales. Its trailing earnings are negative, so it has no PE. Revenue was $508K over the last twelve months, down 7% on a year earlier.

Charts

Financials

Income statement for CRDF, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$141K+52%$156K+22%$205K+147%$163K+51%$165K+17%$151K−3%$109K−47%$121K−26%$120K−27%$243K+61%$41K−62%$104K−14%
Cost of revenuen/an/an/an/an/an/an/an/an/an/an/an/a
Gross profitn/an/an/an/an/an/an/an/an/an/an/an/a
R&D$8M+34%$7.8M+21%$8M−12%$9.5M+18%$9.6M+20%$9.7M+25%$10.5M+31%$11.6M+22%$8.2M−15%$5.1M−48%$6.8M−35%$5.9M−49%
SG&A$2.9M−5%$2.7M−12%$3.1M+2%$3.2M−25%$3.1M+6%$3M+11%$4M+28%$3.3M+3%$3.9M+25%$3M−1%$6.1M+53%$3.8M+15%
−$10.8M+20%−$10.3M+10%−$10.9M−9%−$12.5M+3%−$12.6M+17%−$12.6M+22%−$14.4M+32%−$14.8M+18%−$12M−5%−$7.8M−38%−$12.8M−11%−$9.6M−35%
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
Net income−$9.7M+14%−$9.3M+7%−$10M−11%−$11.8M+6%−$11.9M+22%−$11.8M+26%−$13.4M+34%−$13.9M+18%−$11.3M−5%−$7.2M−39%−$12.3M−8%−$9.2M−34%
−$0.22+10%−$0.21+5%−$0.22−12%−$0.26+4%−$0.25+14%−$0.22+5%−$0.20−9%−$0.21−19%−$0.17−32%−$0.11−50%−$0.18−10%−$0.14−33%
44.7M+3%44.7M+0%44.7M+0%44.8M+0%46.9M+5%54.2M+21%66.5M+49%66.5M+48%66.9M+43%67.4M+25%68.3M+3%68.4M+3%

Gross profit: 21 periods, Q3 FY14 to Q4 FY19: not printed by the filing, worked out from its own lines.

EPS, diluted: 10 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 10 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Cardiff Oncology's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
CRDFCardiff Oncology$65.7Mn/mn/a129×−7%n/m
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
ICCCImmucell$95.9M132×44.1×3.1×+8%2.6%
ATNMActinium Pharmaceuticals$45M4.0×3.3×n/mn/mn/m
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
NEPHNephros$35.2M20.3×28.3×1.7×+24%8.4%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
Peer median$84.7M12.8×18.0×1.3×+7%6.8%

More on Cardiff Oncology

Each number over time

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .